Clinical appearance and treatment of hypertrophic obstructive cardiomyopathy;Klinik und therapie der hypertrophen kardiomyopathie

Medizinische Klinik

Volumn 93, Issue 4, 1998, Pages 260-267

  Gleichmann, Ulrich ^a   Seggewiß, Hubert ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Hypertrophic obstructive cardiomyopathy; Pacemaker implantation; Percutaneous transluminal septal myocardial ablation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; VERAPAMIL;

CLINICAL FEATURE; HEART MUSCLE NECROSIS; HEART OUTFLOW TRACT OBSTRUCTION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MUSCLE RESECTION; MYOTOMY; PROGNOSIS; REVIEW; RISK FACTOR; STRESS; SUDDEN DEATH; SYNCOPE;

EID: 0032522429     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044802     Document Type: Review

References (58)

1. Berghöfer G. Der Einfluß der Septumperfusion auf die Obstruktion, der linksvertrikulären Ausflußbahn bei hypertrophe Kardiomyopathie. 1989; Forschungsantrag (persönliche Mitteilung).
2. Bhargava B, Agarval R., Kaul U, Macbanda SC, Harbans S. Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Diagn 1997;41:56-8.
3. Bircks W, Schulte HD. Surgical treatment of hypertrophic obstructive cardiomyopathy with special reference to complications and to atypical hypertrophic obstructive cardiomyopathy. Eur Heart J 1983;4: Suppl F:187-90
4. Brugada P, de Swart H, Smeets JLRM, Wellens HJJ. Transcoronary chemical ablation of ventricular tachycardia. Circulation 1989;79:475-82.
5. Chang AC, McAreavey D, Fananapazir L. Identification of patients with hypertrophic cardiomyopathy at high risk for sudden death. Curr Opin Cardiol 1995;10:9-15.
6. Faber L, Seggewiss H, Fassbender D, Strick S, Bogunovic N, Gleichmann U. Catheter treatment in hypertrophic obstructive cardiomyopathy: identification of the perfusion area of septal branches by myocardial contrast echocardiography (MCE): First experiences. Eur Heart J 1997;18:Suppl:368.
7. Faber L, Seggewiss H, Fassbender D, Strick S, Gleichmann U. Guiding of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography: a case report, J intervent Cardiol (im Druck).
8. Faber L, Seggewiss H, Fassbender D, Strick S, Schmidt HK, Gleichmann U. Risk factors for permanent tnfascicular heart block after percutaneous transluminal septal mypcardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM): Circulation 1997;96: Suppl I:645.
9. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-42.
10. Frank MJ, Abdulla AM, Canedo MI, Saylors PE. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 1978;42:993-1001
11. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Abnahme der Obstruktion bei hypertropher Kardiomyopathie während passagerer Okklusion des ersten Septalastes der linken Koronarartene. Z Kardiol 1994;83:-Suppl 1:146.
12. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Katheterinterventionelle Therapie der hypertrophisch obstruktiven Kardiomyopathie durch Alkoholablation des ersten Septalastes der linken Koronararterie. Z. Kardiol 1996;85:Suppl 2:3.
13. Gietzen F, Kuhn H, Leuner CH, Gerenkamp T, Hegselmann J, Raute-Kreinsen U. Acute and long-term results after transcoronary ablation of septum hypertrophy in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997;18:Suppl:468.
14. Gleichmann U, Seggewiss H, Faber L, Fassbender D, Schmidt HK, Strick S. Kathetertherapie der hypertrophen obstruktiven Kardiomyopathie. Dtsch Med Wochenschr 1996;21:679-85.
15. Gletchmann U, Seggewiss H. Therapie der hypertrophen obstruktiven Kardiomyopathie. Dtsch Med Wochenschr 1996;121:1485-6.
16. Haberer T, Hess OM, Jenni R, Krayenbühl HP. Hypertrophic obstructive cardiomyopathy: Spontaneous course in comparison to long-term therapy with propanolol and verapamil. Z Kardiol. 1983;72:487-93.
17. Hamada M, Shigematsu Y, Ikeda S, et al. Class Ia antiarrhythmic drug: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997;96:1520-4.
18. Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross Jr J. Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964;29:84-98.
19. Hassenstein P, Storch HH, Schmitz W. Erfahrungen mit der Schrittmacherdauerbehandlung bei Patienten mit obstruktiver Kardiomyopathie. Thoraxchirurgie 1976; 23:496-9.
20. Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy: Early and late results. J Thorac Cardiovasc Surg 1995;110:195-208.
21. Jeanrenaud X, Goy JJ, Kappenberger L, Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992;339:1318-23.
22. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979; 42:35-42.
23. Kappenberger L. Pacing for obstructive hypertrophic cardiomyopathy. Br Heart J 1995;73:107.
24. Kappenberger L, Linde C, Daubert C, et al. Pacing for obstructive hypertrophic cardiomyopathy. Eur Heart J 1997;18:1249-56
25. Kimball BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J 1993;125: 1691-7.
26. Kirklin JW, Ellis Jr FR. Surgical relief of diffuse subvalvular aortic stenosis. Circulation 1961;24.739-42.
27. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992;85:1651-60.
28. Knight C, Kurbaan AS, Seggewiss H, et al. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95.2075-81.
29. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997;18.846-51.
30. Kuhn H, Gietzen F, Schäfers M, et al. Catheter interventional therapy of hypertrophic obstructive cardiomyopathy by transcoronary ablation of septum hypertrophy: changes of the subaortic septum. Eur Heart J 1997,18;Suppl:605.
31. Lakkis N, Kleiman N, Kilhp D, Spencer III WH. Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol 1997,20:417-8.
32. Liberthson RR. Sudden death from cardiac causes in children and young adults N Engl J Med 1996;334: 1039-14
33. Manan AJ, Mares Jr A, Kelly DP, et al. Sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 1995;16:368-76.
34. Maron BJ, Roberts WC, Edwards JE, McAllister HA, Foley DD, Epstein SE. Sudden death in patients with hypertrophic candiomyopathy: Characterization of 26 patients without functional limitations. Am J Cardiol 1978;41.803-10
35. Maron BJ, Roberts WC, McAllister HA, Rosing DR, Epstein SE. Sudden death in young athletes. Circulation 1980;62:218-29.
36. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: Too soon for a rush to judgment? J Am Coll Cardiol 1996;27:431-2.
37. Mc Cully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-71.
38. Mc kenna WJ, akley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985,53:412-6.
39. Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculotomy. Ann Surg 1961;154:181-9.
40. Nishimura RA, Hayes DL, Ilstrup DM, Holmes Jr DR, Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol 1996;27:421-30.
41. Nishimura RA, Trusty JM, Hayes DL et al. Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double blind, crossover trial. J Am Coll Cardiol 1997;29:435-41.
42. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide: N Engl J Med 1982;307:997-9.
43. Robbins RC, Stinson EB, Daily PO. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy, J Thorac Cardiovasc Surg 1996,111:586-94.
44. Romeo F, Pellicia F, Christofani R, Martuscelli E, Reale A. Hypertrophic cardiomyopathy: Is die left venmcular outflow gradient a major prognostic determinant? Eur Heart J 1990;11:233-40.
45. Schoendube FA, Klues HG, Reith S, Flachskampf, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and recristruction of the subvalvular mitral apparatus. Circulation 1995;92:Suppl II:122-7
46. Schulte HD, Gramsch-Zabel H, Schwartzkopff B. Hypertrophe obstruktive Kardiomyopathie: Chirurgische Behandlung Schweiz Med Wochenschr 1995;125: 1940-9.
47. Schulze-Menger JE, Waigand J, Strohm O. Magnetic resonance imaging accurately detects delayed improvement in feft ventricular outflow tract following septal embolization in hypertrophic obstructive cardiomyopathy Circulation 1997,96:Suppl 1:190.
48. Schwartz K. Familial hypertrophic cardiomyopathy: Nonsense versus missense mutations. Circulation 1995;91:2865-7.
49. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S Härnodynamische und klioische Akutergebrusse der Kathetertherapie bei hypertropher obstruktiver Kardiomyopathie. Z Kardiol 1996;85:Suppl 5:460.
50. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Catheter treatment of hypertrophic cardiomyopathy: Acute and mid-term results. J Am Coll Cardiol 1997;29:Suppl A:388A.
51. Seggewiss H, Gleichmaun U, Faber L The management of hypertrophic cardiomyopathy. N Engl J Med 1997;337-349.
52. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients J Am Coll Cardiol 1998;31:252-8.
53. Seggewiss H, Gleichmann U, Meyners W, Boganovic N, Odenthal HJ, Faber L Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: a case report. Cathet Cardiovasc Diagn (im Druck)
54. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995;346: 211-4
55. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743-7.
56. Spirito P, Seidman CE McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
57. Vassalli S. Seiler G, Hess OM. Risk stratification in hypertrophic cardiomyopathy. Curr Opin Cardiol 1994;9: 330-6.
58. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995;92:1680-92.